GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma
Open Access
- 21 March 2022
- journal article
- research article
- Published by Elsevier in Journal of Advanced Research
- Vol. 44, 173-183
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
This publication has 39 references indexed in Scilit:
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2013
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor modelsCancer Letters, 2013
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyJournal of Clinical Oncology, 2013
- Expression of glutathione peroxidase 2 is associated with not only early hepatocarcinogenesis but also late stage metastasisToxicology, 2013
- Glutathione peroxidasesBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinomaJournal of Experimental & Clinical Cancer Research, 2013
- Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species ProductionIn VitroandIn VivoMolecular Cancer Therapeutics, 2012
- Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinomaBMC Cancer, 2012
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Activation of the glutathione peroxidase 2 (GPx2) promoter by β-cateninBiological Chemistry, 2007